Wednesday, April 25, 2018 7:32:17 PM
Opko Health Inc (NASDAQ:OPK) has an ABR of 2.2 which is the combined stock view of 5 analysts poll results. As per Zacks simplified descending rating scale the ABR rank is displayed in the range of 1 to 5 where 1 represents Strong Buy and 5 a Strong Sell. As the name implies that ABR will show you the Average of Brokerage Recommendations on a given stock. It helps you quickly get a picture of where Wall Street stands on a stock without reading huge research reports. The smaller number of ABR is the more favorable. The modest value of the stock is known as the current ABR of the stock.
However out of 5 analysts 1 suggest Opko Health Inc (NASDAQ:OPK) a Strong Buy, 3 suggested Buy, 1 Hold and 1 Sell, while 0 analysts recommend the stock a Strong Sell.
Analysts are expecting average earnings estimates of $-0.13 for the current quarter based on the opinion of 5 analysts, relating to high earnings per share estimates of $-0.1 and low estimates of $-0.16, however Opko Health Inc (NASDAQ:OPK) reported $-0.06 earnings per share for the same quarter last year.
For the current quarter Opko Health Inc (NASDAQ:OPK) has average revenue estimates of $236.9 Million, a total number of 5 analysts provided estimations over revenues. However the low revenue estimates for the company are $197.6 Million versus high revenue estimates of $253 Million. A year ago the company’s sales were $296100 while its sales growth yearly estimates for the current quarter are -20%.
Taking a broader look at the analyst consensus, brokerage firms have a price target of $11.9 on Opko Health Inc (NASDAQ:OPK). Brokerage firms on the street have price targets on the name ranging from $3.5 to $20 based on 5 opinions.
Opko Health Inc (NASDAQ:OPK) as of current trade, has shown weekly performance of -3.54% which was maintained at -8.26% in one month period. Year to date performance remained at -38.78%. During the past three months the stock gain -37.89%, however six months performance of the stock remained at -56.9%. Opko Health Inc (NASDAQ:OPK)’s price sits -11.1% off from its SMA 50 of $3.23 and -42.23% away from the SMA 200 which is at $4.65.
Currently Opko Health Inc (NASDAQ:OPK)’s shares owned by insiders are 1.6%, whereas shares owned by institutional owners are 24.2%. However the six-month change in the insider ownership was recorded 43.76%, as well as three-month change in the institutional ownership was recorded 0.44%.
The stock is trading -62.01% away from its 52 week high of $7.90 and 12.78% far from the stock’s low point over the past 52 weeks, which was $2.66.
The price-earnings ratio (P/E ratio) is the ratio for valuing a company that measures its current share price relative to its per-share earnings. Opko Health Inc (NASDAQ:OPK)’s price to earnings ratio stood at 0. A high P/E suggests that investors are expecting higher earnings growth in the future compared to companies with a lower P/E. A low P/E can indicate either that a company may currently be undervalued or that the company is doing exceptionally well relative to its past trends.
The PEG ratio is used to determine a stock’s value while taking the company’s earnings growth into account, and is considered to provide a more complete picture than the P/E. Opko Health Inc (NASDAQ:OPK) has a current PEG of 0. Opko Health Inc (NASDAQ:OPK)’s price to sales ratio for trailing twelve month stands at 1.64, whereas its price to book ratio for the most recent quarters is at 0.89. However the company’s price to cash per share for most recent quarter stands at 0. Its price to free cash flow for trailing twelve months is 0.
https://emnnews.com/2018/04/25/experts-analysis-opko-health-inc-opk-2/
Recent OPK News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/07/2024 08:29:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/07/2024 08:07:44 PM
- OPKO Health Reports First Quarter 2024 Business Highlights and Financial Results • GlobeNewswire Inc. • 05/07/2024 08:05:00 PM
- OPKO Health to Report First Quarter 2024 Financial Results on May 7, 2024 • GlobeNewswire Inc. • 05/03/2024 12:00:00 PM
- Labcorp Announces Acquisition of Select Assets of BioReference Health's Diagnostics Business • PR Newswire (US) • 03/28/2024 12:00:00 PM
- Entera Bio Announces Robust Pharmacokinetic Data for First-in-Class Oral GLP-2 Peptide Tablet Treatment for Patients with Short Bowel Syndrome • GlobeNewswire Inc. • 03/20/2024 12:00:00 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/07/2024 09:02:37 PM
- AIDS Clinical Trial Group Presents Results from Phase 1 Study of ModeX Trispecific Antibody for the Treatment and Prevention of HIV • GlobeNewswire Inc. • 03/05/2024 01:52:22 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/01/2024 09:05:23 PM
- NextPlat Opens OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China on March 1st • PR Newswire (US) • 02/28/2024 02:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 09:07:54 PM
- OPKO Health Reports Fourth Quarter 2023 Business Highlights and Financial Results • GlobeNewswire Inc. • 02/27/2024 09:05:00 PM
- OPKO Health to Report Fourth Quarter 2023 Financial Results on February 27, 2024 • GlobeNewswire Inc. • 02/22/2024 09:05:00 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 02/16/2024 09:53:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2024 09:07:24 PM
- NextPlat Receives Initial Approvals to Launch OPKO Health-Branded Storefront on Alibaba's Tmall Global Platform in China • PR Newswire (US) • 02/05/2024 01:09:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/29/2024 08:30:14 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 01/24/2024 09:15:49 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 09:00:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/17/2024 10:09:48 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/10/2024 10:56:45 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/09/2024 10:09:07 PM
- OPKO Health Announces Closing of Private Offering of $230 Million Convertible Senior Notes Due 2029 including Full Exercise of Initial Purchaser’s Option to Purchase Additional Notes • GlobeNewswire Inc. • 01/09/2024 09:05:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/08/2024 02:10:34 PM
- OPKO Health to Present at the 42nd Annual J.P. Morgan Healthcare Conference • GlobeNewswire Inc. • 01/08/2024 01:00:00 PM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM
Avant Technologies Engages Wired4Tech to Evaluate the Performance of Next Generation AI Server Technology • AVAI • May 23, 2024 8:00 AM
Branded Legacy, Inc. Unveils Collaboration with Celebrity Tattoo Artist Kat Tat for New Tattoo Aftercare Product • BLEG • May 22, 2024 8:30 AM
"Defo's Morning Briefing" Set to Debut for "GreenliteTV" • GRNL • May 21, 2024 2:28 PM
North Bay Resources Announces 50/50 JV at Fran Gold Project, British Columbia; Initiates NI 43-101 Resources Estimate and Bulk Sample • NBRI • May 21, 2024 9:07 AM